What is the evidence base for Melanotan I?

Melanotan I's evidence base sits at phase iii in epp; off-label tanning use. The references on this page summarise 1 primary publication supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The female physiology interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

What does Melanotan I stack well with?

For female physiology protocols, Melanotan I pairs with compounds on complementary pathways: Oxytocin, Kisspeptin, GHK-Cu. These pairings are selected because they engage independent receptor systems from Melanotan I's primary mechanism (Selective melanocortin-1 receptor (MC1R) agonist), producing additive or synergistic effects rather than receptor competition.

Is Melanotan I safe during pregnancy or breastfeeding?

Melanotan I, like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

What should I look for in Melanotan I sourcing and quality?

Acceptable Melanotan I certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching 1646 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

Should I cycle Melanotan I?

Standard cycle for Melanotan I is 8–12 weeks of 1x daily during loading; less frequent maintenance 0.5-1 mg dosing via subq/implant (approved formulation), followed by a 4 week complete off-period. The off-period is calibrated to Melanotan I's ~2-30 days (implant); ~30 min SubQ half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

Home/ Compounds/ Melanotan I

Melanotan I

Women's Health

For women considering Melanotan I, the framework spans three life stages: reproductive, perimenopausal, and postmenopausal. Each carries distinct hormonal context and distinct monitoring requirements. The non-cyclic α-MSH analogue with selective MC1R activity — FDA-approved as an implant for erythropoietic protoporphyria. The ~2-30 days (implant); ~30 min SubQ pharmacokinetic profile shapes how the compound is felt across follicular versus luteal phases in pre-menopausal users and how it integrates with HRT in older cohorts.

Female Physiology Applications

PerimenopauseBody Composition (Female)Vaginal HealthHair HealthEndometriosis Support

Key Takeaways

Female-physiology lens: Melanotan I response varies across follicular and luteal phases for premenopausal users; integrates with HRT in perimenopause and postmenopause.
Mechanism: Selective melanocortin-1 receptor (MC1R) agonist.
Female monitoring: cycle-day-appropriate estradiol, progesterone, FSH, LH, prolactin, TSH, bone markers; pregnancy contraindication is default.
Female dose: 0.5-1 mg 1x daily during loading; less frequent maintenance via subq/implant (approved formulation); cycle-phase tracking for 1-2 cycles.
Female-physiology stack partners: Oxytocin, Kisspeptin, GHK-Cu.

Female Physiology Mechanism

Cyclical hormone background shapes how women experience Melanotan I. Selective melanocortin-1 receptor (MC1R) agonist. Increases eumelanin production in melanocytes. Provides photoprotection. Lacks the MC4R-mediated central effects (libido, appetite, sexual response) of Melanotan II. For premenopausal users, phase-aware tracking across 1-2 cycles informs the schedule; for perimenopausal users, HRT integration is the dominant question; for postmenopausal users, bone density and cardiovascular tone become the priority considerations.

Cyclical and hormonal context

Female physiology is cyclical in a way that male physiology is not, and Melanotan I's effects often vary across follicular versus luteal phase. Even where the compound's pharmacology is not directly hormonal, the cyclical hormone background influences how it is metabolised, distributed, and felt. Pre-menopausal users should expect to track response by cycle phase for one or two cycles before settling on a fixed schedule.

Perimenopause and menopause integration

For women in the perimenopausal or post-menopausal window, Melanotan I is most effective when integrated with the broader hormonal picture — HRT (estrogen, progesterone, sometimes testosterone), bone-density support, and cardiometabolic monitoring. Many compounds in this category produce stronger effects in this window precisely because the surrounding hormonal landscape is changing.

Fertility and reproductive considerations

Melanotan I's effect on fertility-relevant endpoints — ovulation, ovarian reserve markers, uterine receptivity, lactation — deserves explicit consideration for women in the reproductive window. Most well-studied compounds have minimal direct effect on reproductive endpoints at therapeutic doses, but pregnancy and active conception remain explicit contraindications for most non-approved peptides.

Female Physiology Applications

Perimenopause

Perimenopause is one of the dimensions on which women track Melanotan I response. Effect size depends on baseline hormonal status and on integration with HRT or contraception. Tracking by cycle phase for the first 1–2 cycles informs subsequent scheduling.

Cardiovascular (Female)

For cardiovascular (female) in female users, Melanotan I is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.

Fertility

In the perimenopausal window, Melanotan I for fertility produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.

Sleep

Sleep is one of the dimensions on which women track Melanotan I response. Effect size depends on baseline hormonal status and on integration with HRT or contraception. Tracking by cycle phase for the first 1–2 cycles informs subsequent scheduling.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	0.5-1 mg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	1.5-1 mg	4–6 weeks initial cycle
Women's Health focus	SubQ	0.5-1 mg	1x daily during loading; less frequent maintenance
Maintenance phase	SubQ	1.5-1 mg	Ongoing with periodic pauses

Dose timing for Melanotan I is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Melanotan I stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from women's-health clinicians.

Melanotan I + Oxytocin: Activates oxytocin receptors (OXTR) peripherally (uterine smooth muscle, mammary alveoli) and centrally (amygdala, hypothalamus, ventral tegmentum). Pairs naturally with Melanotan I's mechanism in female physiology protocols.
Melanotan I + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with Melanotan I's mechanism in female physiology protocols.
Melanotan I + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with Melanotan I's mechanism in female physiology protocols.
Melanotan I + Epithalon: Identified by Khavinson in St. Pairs naturally with Melanotan I's mechanism in female physiology protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Approved (Scenesse implant for EPP) Research: Phase III in EPP; off-label tanning use

Hyperpigmentation (intended). Nausea on initial doses. Watch for new/changing moles. Avoid in personal/family melanoma history.

Lens-specific safety considerations for female physiology use of Melanotan I: Hyperpigmentation (intended). Nausea on initial doses. Watch for new/changing moles. Avoid in personal/family melanoma history. Additional female physiology monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Afamelanotide in erythropoietic protoporphyria

PMID 26177253

Melanotan I vs Related Peptides

Compound	Profile	Onset	Best For
Melanotan I	α-MSH analogue (long-acting)	~2-30 days (implant); ~30 min SubQ	Women's Health
Oxytocin	Posterior pituitary nonapeptide	~1-6 min plasma; CNS longer	The 'bonding hormone' — a posterior pituitary nonapeptide with effects on uterine contraction, lactation, and a wide range of social and sexual behaviour via central oxytocin receptors
Kisspeptin	Hypothalamic upstream regulator of GnRH	~28 min IV	The upstream master regulator of GnRH neurons — driving the entire HPG axis from above
PT-141	Melanocortin receptor agonist	~2-3 hr	An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women

Frequently Asked Questions

Is Melanotan I appropriate during perimenopause?

Yes, and many women report stronger response in the perimenopausal window than at younger ages. The interaction with HRT — estrogen, progesterone, sometimes testosterone — is generally additive rather than competitive. Bone density, cardiovascular, and metabolic monitoring continues to apply.

Does Melanotan I affect bone density?

Several peptide compounds have measurable effects on bone-remodelling markers, particularly relevant for post-menopausal users. Where Melanotan I specifically engages this pathway, paired pre-post DEXA or bone-marker tracking provides the cleanest evaluation. For most compounds the bone effect is secondary and develops over months.

Will Melanotan I affect contraceptive efficacy?

For most peptide compounds, contraceptive efficacy is not significantly affected. Compounds directly modulating the HPG axis (kisspeptin, gonadorelin) are exceptions and warrant alternative or additional contraceptive measures during use. Melanotan I's specific interaction follows its mechanism.

Can I use Melanotan I alongside HRT?

Yes, in most cases. Integration with HRT — estrogen, progesterone, sometimes testosterone — is additive rather than competitive for most peptide compounds. Coordinating with a HRT-prescribing physician on dose timing and monitoring is the standard approach.

How does Melanotan I's half-life affect dosing?

Melanotan I has a plasma half-life of ~2-30 days (implant); ~30 min SubQ, which is short enough to require multiple daily doses to maintain therapeutic exposure. The receptor occupancy curve under 1x daily during loading; less frequent maintenance dosing at 0.5-1 mg per dose explains the typical onset timeline for female hormonal and cyclical endpoints.

What route should I use for Melanotan I?

Melanotan I is delivered by subq/implant (approved formulation). Subcutaneous administration is standard for ${o.cat.toLowerCase()} class peptides and provides reliable systemic bioavailability. The choice depends on target system and convenience.

Clinical Protocol

Start a Melanotan I Protocol

Alukard provides physician-supervised women's health protocols with GMP-certified Melanotan I and Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get Protocol

Quick Facts

Molecular weight: 1646 Da
Sequence length: 13 aa
Half-life: ~2-30 days (implant); ~30 min SubQ
WADA: Not on prohibited list
FDA: Approved (Scenesse implant for EPP)
Research: Phase III in EPP; off-label tanning use

Stack Partners

Oxytocin

Kisspeptin

GHK-Cu

Epithalon

PT-141

Research Note

All female physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Melanotan I unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised women's health protocols

Start Your Female Physiology Protocol for Melanotan I

Alukard provides physician-supervised women's health protocols with Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised